Sophiris Bio Inc (SPHS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sophiris Bio Inc (SPHS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10160
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sophiris Bio Inc (Sophiris) is a clinical stage bio-pharmaceutical company, which focuses on developing products for the treatment of urological diseases. Sophiris lead drug candidate, PRX302 is under late stage development for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate. It is a modified recombinant protein that is delivered through ultrasound-guided injection directly into the prostate. This drug is engineered to be active only in prostate tissue. The company’s PRX302 is also being developed for the treatment of low to intermediate risk prostate cancer. Sophiris is headquartered in La Jolla, California, the US.

Sophiris Bio Inc (SPHS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sophiris Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Sophiris Bio Raises USD26 million in Public Offering of Shares and Warrants 10
Sophiris Bio Raises USD5 Million in Public Offering of Shares and Warrants 12
Sophiris Bio Completes First Tranche of Private Placement of Shares for USD2 Million 13
Sophiris Bio Completes Public Offering Of Shares For US$65 Million 14
Sophiris Bio Inc – Key Competitors 15
Sophiris Bio Inc – Key Employees 16
Sophiris Bio Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Aug 14, 2018: Sophiris Bio reports second quarter 2018 financial results and recent corporate highlights 18
May 14, 2018: Sophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate Highlights 20
Mar 21, 2018: Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights 22
Nov 09, 2017: Sophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights 24
Aug 10, 2017: Sophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights 26
May 15, 2017: Sophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights 28
Mar 27, 2017: Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights 29
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sophiris Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sophiris Bio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sophiris Bio Raises USD26 million in Public Offering of Shares and Warrants 10
Sophiris Bio Raises USD5 Million in Public Offering of Shares and Warrants 12
Sophiris Bio Completes First Tranche of Private Placement of Shares for USD2 Million 13
Sophiris Bio Completes Public Offering Of Shares For US$65 Million 14
Sophiris Bio Inc, Key Competitors 15
Sophiris Bio Inc, Key Employees 16
Sophiris Bio Inc, Subsidiaries 17

List of Figures
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Sophiris Bio Inc (SPHS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Oando Energy Resource Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Oando Energy Resource Inc (Oando), a subsidiary of Oando Plc, is an exploration and production company that carries out upstream exploration and development programs. The company provides investments in a portfolio of oil and gas fields, and provides participation of interests in onshore and …
  • A.P. Moller – Maersk AS (MAERSK B)-石油・ガス分野:企業M&A・提携分析
    Summary A.P. Moller - Maersk A/S (APM) is a business conglomerate that carries out operations in global trade, shipping and energy. It operates through a network of tankers, supply ships, container vessels, car carriers, drilling rigs and special vessels. The company also carries out container termi …
  • Mr. Price Group Ltd.:企業の戦略・SWOT・財務情報
    Mr. Price Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mr. Price Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • NeuroLogica Corp:医療機器:M&Aディール及び事業提携情報
    Summary NeuroLogica Corp (NeuroLogica), a subsidiary of Samsung Electronics America Inc is a medical device company that develops, manufactures and markets medical imaging equipment. The company offers digital radiography systems for hospitals and imaging centers, portable CT imaging systems, and ul …
  • Next Plc:企業の戦略・SWOT・財務情報
    Next Plc - Strategy, SWOT and Corporate Finance Report Summary Next Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Airest S.p.A.:企業の戦略・SWOT・財務情報
    Airest S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Airest S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Avingtrans Plc (AVG):企業の財務・戦略的SWOT分析
    Avingtrans Plc (AVG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Banque Marocaine du Commerce Exterieur SA:企業の戦略・SWOT・財務分析
    Banque Marocaine du Commerce Exterieur SA - Strategy, SWOT and Corporate Finance Report Summary Banque Marocaine du Commerce Exterieur SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • S P Setia Berhad (SPSETIA):企業の財務・戦略的SWOT分析
    S P Setia Berhad (SPSETIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Monopar Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Monopar Therapeutics LLC (Monopar) is a biopharmaceutical company that develops orphan oncology compounds. The company’s pipeline product include huATN-658, a humanized monoclonal antibody for the potential treatment of various cancers including pancreatic cancer, ovarian cancer, and others. …
  • Esprinet S.p.A. (PRT):企業の財務・戦略的SWOT分析
    Esprinet S.p.A. (PRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Computershare Limited (CPU):企業の財務・戦略的SWOT分析
    Computershare Limited (CPU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Toyo Seikan Group Holdings, Ltd.:企業の戦略・SWOT・財務分析
    Toyo Seikan Group Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toyo Seikan Group Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Japan Pulp and Paper Co Ltd:戦略・SWOT・企業財務分析
    Japan Pulp and Paper Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Pulp and Paper Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Penta-Ocean Construction Co Ltd
    Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Cavion LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Cavion LLC (Cavion), formerly Tau Therapeutics LLC is a clinical stage pharmaceutical company that develops modulators and drugs. The company researches and develops T-type calcium channel (Cav3) inhibitors for the treatment of neurologic and oncologic diseases. It provides pipeline products …
  • UBS Group AG:企業のM&A・事業提携・投資動向
    UBS Group AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's UBS Group AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Northern Superior Resources Inc (SUP):企業の財務・戦略的SWOT分析
    Summary Northern Superior Resources Inc (Northern Superior) formerly Superior Diamonds Inc, is a mineral exploration company. The company's activities include acquisition and development of gold, and other mineral properties. Its projects include Croteau Est gold property, LAC surprise gold property …
  • American Tower Corp (AMT):企業の財務・戦略的SWOT分析
    American Tower Corp (AMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Bord na Mona Plc:企業の戦略的SWOT分析
    Bord na Mona Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆